RxDoctor Payments Data

Mingi Choi, OD

Optometrist · Arlington, TXNPI 1174017453

Payments from drug & device makers

$2,389in general payments, 2019–2025

Across 98 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$656
  • Alcon$470
  • Bausch & Lomb Americas Inc.$360
  • Biotissue Holdings Inc.$168
  • Tarsus Pharmaceuticals, Inc.$93
  • Harrow Eye, LLC$93
  • plus $550 from 13 others

What the payments were for

  • Food & beverage$2,389100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,389 in reported general payments places this provider in the 75th percentile of 4,315 optometrist providers in Texas.

See all optometrist providers in Texas

Medicare billing

Part B allowed, 2024
$97,889
Medicare patients
592
Services billed
1,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine45$46,156
LumiganBimatoprost67$28,280
Cyclosporine22$13,895
MieboPerfluorohexyloctane/Pf12$12,177
RocklatanNetarsudil Mesylat/Latanoprost16$12,077
VyzultaLatanoprostene Bunod19$9,660
CombiganBrimonidine Tartrate/Timolol19$6,816
SimbrinzaBrinzolamide/Brimonidine Tart21$6,280
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol46$5,855
Latanoprost390$3,801
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat157$2,901
Prednisolone Acetate50$2,090
Timolol Maleate154$1,639
Azelastine Hcl27$815
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha68$777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$656$81,251131 claims
Bausch & Lomb Americas Inc.Miebo, Vyzulta$360$21,83731 claims
Aerie Pharmaceuticals, Inc.Rocklatan$22$12,07716 claims
AlconSimbrinza$470$6,28021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,315 optometrist providers in Texas.

Other optometrist in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →